National Institute of Allergy and Infectious Diseases (NIAID)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).
National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.
National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.
Top-decile sponsor footprint
National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,006 total, page 24 of 41
Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma
NCT00307177
Collection of Specimens for Study of Inflammatory Bowel Disease
NCT00086554
Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents
NCT00075907
Rapid HIV Testing for Emergency Department Patients
NCT00676481
Atazanavir/Ritonavir Maintenance Therapy
NCT00084019
Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)
NCT00078403
Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV
NCT00086359
Blood Levels of Abacavir in HIV Infected Adolescents
NCT00087945
Experimental Vaccine for Plasmodium Falciparum Malaria
NCT00340431
Omalizumab to Treat Eosinophilic Gastroenteritis
NCT00084097
Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients
NCT00085917
An Interventional Study of Milk Allergy
NCT00578656
Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients
NCT00080106
Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines
NCT00138255
Safety and Immunogenicity of an HIV Vaccine in Normal Adult Volunteers
NCT00083330
Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients
NCT00082498
Study of Tolerant Kidney Transplant Recipients
NCT01338779
Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients
NCT00001131
Combination Study With MVA BN and Dryvax
NCT00082446
Anti-CD20 Antibody Therapy for Sjogren's Syndrome
NCT00101829
Dryvax Dilution-Prev Vacc Adults
NCT00032708
Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP
NCT00076037
Directly Observed Therapy in HIV Infected Adolescent Focus Groups
NCT00079729
Daclizumab to Treat HIV-Infected Patients
NCT00080431
A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines
NCT00076063
Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation
NCT00141037
Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants
NCT00076791
Exhaled Breath Condensate as a Measure of Airway Inflammation in Children With Asthma
NCT00078208
Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis
NCT00396084
Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV
NCT00084149
Leukapheresis for Research on HCV-Coinfected Patients
NCT00076427
Factors Affecting Adherence to Anti-HIV Drug Regimens in Children and Adolescents
NCT00073424
An Observational Study of People Who Have Recently Been Infected With HIV
NCT00103961
GW873140 to Treat HIV-1 Infected Adults
NCT00076284
Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults
NCT00071851
Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults
NCT00069030
Umbrella Study for HIV Infected Adults Enrolled in NIAID-Funded Interleukin-2 Studies
NCT00311688
Experimental Ebola Vaccine Trial
NCT00072605
A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth
NCT00069004
An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
NCT00072592
Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx
NCT00071890
Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults
NCT00051831
VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases
NCT00068926
Novel Protective Underglove
NCT00170586
Immune Response to Influenza Vaccine in HIV-Infected Individuals
NCT00069914
IVIG - West Nile Encephalitis: Safety and Efficacy
NCT00068055
West Nile Virus Natural History
NCT00138463
Investigating Severe Acute Respiratory Syndrome (SARS)
NCT00066209
Chiron Corp HCV E1/E2 Vaccine
NCT00500747
Safety of the EnvPro HIV Vaccine in Healthy Volunteers
NCT00076947
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 858 |
| Phase 2 | 433 |
| Phase 3 | 123 |
| Phase 4 | 54 |
Therapeutic Areas
What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline
155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).
Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).
Top condition: HIV Infections (195 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide
Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,006 trials (± recruiting share)
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page
2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.
- 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.